Page 5 - Anders Ullman News Today

Investegate announcements from Sanofi - Aventis Groupe, Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A

Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA Designation is based on XTEND-1 phase 3 study data demonstrating a clinically

Designation is based on XTEND-1 phase 3 study data demonstrating a clinically meaningful prevention of...

FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDADesignation

01.06.2022 - FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDADesignation is based on XTEND-1 Phase 3 study data ... Seite 1

Sobi ® will present new data at the hybrid EHA (European Haematology Association) congress taking place in Vienna from 9-17 June 2022, highlighting the companys commitment in rare haematological diseases

Efanesoctocog alfa significantly and meaningfully reduces annualised bleeding rates in haemophilia A patients.

Investegate announcements from Sanofi - Aventis Groupe, Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)...

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection)...